Rhythm Pharmaceuticals, Inc. RYTM

Set alert

Price alert · RYTM

All alert types
93.44 USD +0.87 +0.94%

At close · Nov 2

93.44 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
93.52 × 2
Ask
93.70 × 2
93.04 Day range 95.06
74.50 52-week range 122.20
YTD
-12.71%
1 year
-17.86%
Open
93.13
Prev close
92.57
Mkt cap
6.41B
Vol
2.00M
Avg vol
658.96K
EPS
-3.12
P/E
0.00
Div yield
0.00%
More statistics
Low
93.04
High
95.06
Forward P/E
-148.67
Beta
2.13
Short ratio
13.64
Inst. own
115.08%
Dividend
0.00
Ex-div date
Earnings
Nov 3, 2026
50-d avg
97.18
200-d avg
97.09
1y target
140.53

3M chart

Chart tools
Interval

Events in this range
  • Aug 4, 2026Earnings: -0.73; estimate -0.80721; surprise 9.57%
  • Aug 7, 2026Rating: JP Morgan · Overweight → Overweight
  • Aug 28, 2026Rating: Deutsche Bank · — → Hold
  • Oct 8, 2026Rating: RBC Capital · Outperform → Outperform
  • Oct 12, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 15, 2026Rating: JP Morgan · Overweight → Overweight
  • Oct 16, 2026Rating: William Blair · — → Outperform
Signals (13)
NameDateAgo
SMA: BullishOct 29, 20264 days ago
MACD: Buy SignalOct 20, 20261 week ago
RSI: OversoldOct 16, 20262 weeks ago
RSI: OversoldOct 13, 20262 weeks ago
RSI: OversoldOct 2, 20261 month ago
SMA: BearishAug 28, 20262 months ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 21, 20262 months ago
SMA: BearishAug 20, 20262 months ago
MACD: Sell SignalAug 20, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BullishAug 5, 20262 months ago
SMA: BullishAug 3, 20263 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 140.53 +50.4% upside
Target (low)
120.00
Target (mean)
140.53
Target (high)
160.00
Ratings (0m) 19 17 buy · 2 hold · 0 sell
  • Strong buy5
  • Buy12
  • Hold2
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 19
  • 1 month ago 18
  • 2 months ago 17

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

RYTM analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.74252-0.85 – -0.66-0.82+9.4%84.60M+64.9%13
Next quarter-0.72859-0.93 – -0.57-0.73+0.2%99.17M+73.2%13
Current year-3.04-3.36 – -2.82-3.11+2.1%315.27M+66.1%13
Next year-0.6285-2.45 – 0.49-3.04+79.3%565.12M+79.3%13

Upgrades and downgrades

The latest rating changes

RYTM analyst upgrades and downgrades
DateFirmActionFromTo
Oct 16, 2026William BlairInitiated—Outperform
Oct 15, 2026JP MorganMaintainedOverweightOverweight
Oct 12, 2026HC Wainwright & Co.MaintainedBuyBuy
Oct 8, 2026RBC CapitalMaintainedOutperformOutperform
Aug 28, 2026Deutsche BankInitiated—Hold
Aug 7, 2026JP MorganMaintainedOverweightOverweight
Aug 5, 2026CitigroupMaintainedBuyBuy
Aug 5, 2026RBC CapitalMaintainedOutperformOutperform
Aug 5, 2026CitizensMaintainedMarket OutperformMarket Outperform
Jul 27, 2026JP MorganInitiated—Overweight
Jul 7, 2026RBC CapitalMaintainedOutperformOutperform
Jun 16, 2026Canaccord GenuityMaintainedBuyBuy
Jun 15, 2026Wells FargoMaintainedOverweightOverweight
May 7, 2026Canaccord GenuityMaintainedBuyBuy
May 6, 2026RBC CapitalMaintainedOutperformOutperform
May 6, 2026Wells FargoMaintainedOverweightOverweight
Mar 23, 2026HC Wainwright & Co.MaintainedBuyBuy
Mar 20, 2026CitigroupMaintainedBuyBuy
Mar 20, 2026B of A SecuritiesMaintainedBuyBuy
Mar 20, 2026CitizensMaintainedMarket OutperformMarket Outperform
Mar 18, 2026HC Wainwright & Co.MaintainedBuyBuy
Mar 17, 2026CitigroupMaintainedBuyBuy
Mar 17, 2026RBC CapitalMaintainedOutperformOutperform
Mar 17, 2026CitizensMaintainedMarket OutperformMarket Outperform
Mar 17, 2026B of A SecuritiesMaintainedBuyBuy
Mar 17, 2026Morgan StanleyMaintainedOverweightOverweight
Mar 17, 2026NeedhamMaintainedBuyBuy
Mar 12, 2026Wells FargoMaintainedOverweightOverweight
Mar 2, 2026Canaccord GenuityMaintainedBuyBuy
Mar 2, 2026HC Wainwright & Co.MaintainedBuyBuy